110 related articles for article (PubMed ID: 30943052)
1. Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma.
Biccler JL; Savage KJ; Brown PDN; Jørgensen J; Larsen TS; Poulsen CB; Stoltenberg D; Sehn LH; Scott DW; Gerrie AS; Jakobsen LH; Bøgsted M; El-Galaly TC; Villa D
Leuk Lymphoma; 2019 Oct; 60(10):2516-2523. PubMed ID: 30943052
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
[TBL] [Abstract][Full Text] [Related]
3. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.
Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301
[TBL] [Abstract][Full Text] [Related]
4. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
5. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands.
van der Sanden GA; Schouten LJ; van Dijck JA; van Andel JP; van der Maazen RW; Coebergh JW;
Cancer; 2002 Mar; 94(5):1548-56. PubMed ID: 11920513
[TBL] [Abstract][Full Text] [Related]
7. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience.
Chanswangphuwana C; Rojnuckarin P; Cherdchoo N; Raiyawa T; Uaprasert N
Hematology; 2018 Aug; 23(7):385-390. PubMed ID: 29256330
[TBL] [Abstract][Full Text] [Related]
8. Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma.
Zhuang L; Lai J; Chen K; Ding T; Yuan Y; Ma Y; Kang H; Lin Z; Fan N; Ma J; Zeng Q; Xu X; Wang Q; Chen B
Oncol Rep; 2019 Jan; 41(1):397-404. PubMed ID: 30320386
[TBL] [Abstract][Full Text] [Related]
9. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
[TBL] [Abstract][Full Text] [Related]
10. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004.
Shibamoto Y; Ogino H; Suzuki G; Takemoto M; Araki N; Isobe K; Tsuchida E; Nakamura K; Kenjo M; Suzuki K; Hosono M; Tokumaru S; Ishihara S; Kato E; Ii N; Hayabuchi N
Neuro Oncol; 2008 Aug; 10(4):560-8. PubMed ID: 18559969
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Cheong JW; Kim YR; Lee JY; Jang JE; Kim Y; Min YH; Kim JS
Ann Hematol; 2017 Jul; 96(7):1163-1173. PubMed ID: 28508176
[TBL] [Abstract][Full Text] [Related]
13. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system lymphoma.
Mohile NA; Abrey LE
Neurol Clin; 2007 Nov; 25(4):1193-207, xi. PubMed ID: 17964031
[TBL] [Abstract][Full Text] [Related]
15. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Karmali R; Nabhan C; Petrich AM; Raizer J; Peace D; Lukas R; Gordon LI; Basu S; Chukkapalli V; Venugopal P
Br J Haematol; 2017 Apr; 177(1):72-79. PubMed ID: 28211579
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
17. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B; Ihorst G; Schroers R; Korfel A; Schmidt-Wolf I; Egerer G; von Baumgarten L; Röth A; Bloehdorn J; Möhle R; Binder M; Keller U; Lamprecht M; Pfreundschuh M; Valk E; Fricker H; Schorb E; Fritsch K; Finke J; Illerhaus G
Leukemia; 2017 Dec; 31(12):2623-2629. PubMed ID: 28559537
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
